Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Parabilis Medicines (NASDAQ:PBLS) Ticks Higher: Why Investors Are Reassessing the Stock

Parabilis Medicines, Inc. (NASDAQ:PBLS) has been one of the more talked-about biotech debutants of 2026, and its shares ticked up 1.54% to $36.88 at last closing after a strong post-IPO run. The company is attempting something the industry has long chased: drugging targets that …

Nitish Kishor | 14 September 2026

SI-BONE (NASDAQ: SIBN) Estimates Up to $150,000 iFuse TORQ Recall Charge

The company says third-quarter revenue is not otherwise expected to be affected, while additional on-hand inventory should support implant availability for physicians and patient treatment.

Vinay Lochav | 14 September 2026

Regentis Biomaterials (NYSE American:RGNT) Drifts Lower: Is the Pullback Creating a New Setup?

Regentis Biomaterials Ltd (NYSE American:RGNT) occupies a very different corner of healthcare from the billion-dollar biotechs dominating headlines. Shares closed down 3.57% at $1.89 at last closing, a small move for a thinly traded stock, and one without any confirmed news behind it. The …

Nitish Kishor | 14 September 2026

Skye Bioscience (NASDAQ: SKYE) Keeps Nasdaq Listing After $1.00 Compliance

Skye Bioscience, Inc. (NASDAQ: SKYE) regained compliance with Nasdaq’s minimum bid-price requirement after its common stock recorded a closing bid price of at least $1.00 per share from August 24 through September 4. The development coincided with the termination of its Master Services Agreement …

Vinay Lochav | 14 September 2026

Atrium Therapeutics (NASDAQ:RNA) Shares Little Changed: Why Is the Stock Under Watch?

Atrium Therapeutics, Inc. is a fresh face onNasdaqwearing a familiar badge: the company inherited the well-known RNA ticker when it became an independent, publicly tradedBusinessearlier in 2026. Shares closed essentially flat at last closing, up 0.10% at $10.36, fitting the pattern of a small, …

Nitish Kishor | 14 September 2026

TENAX Therapeutics (NASDAQ: TENX) Bases ING Stake on 37,423,917 Shares

TENAX Therapeutics, Inc. (NASDAQ: TENX) lists ING Groep N.V. And ING Capital Markets LLC at 0.00% beneficial ownership, with neither reporting person holding common stock as of September 11, 2026. The update covers the two entities’ passive ownership position in Tenax common stock.

Vinay Lochav | 14 September 2026

Scribe Therapeutics (NASDAQ:SCTX) Ticks Higher: Is This a Turning Point or Just Noise?

A newly public CRISPR company edged higher in September 2026, and the move offered a reminder that fresh biotech listings rarely trade in a straight line. Scribe Therapeutics Inc (NASDAQ:SCTX), which debuted on the Nasdaq only weeks earlier, closed up 0.92% at $29.74 at …

Nitish Kishor | 14 September 2026

Tenaya Therapeutics Awards 49,000 Shares to CMO (NASDAQ: TNYA)

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) awarded Chief Medical Officer Tingley Whittemore 49,000 shares at $0 per share on September 10, 2026. Whittemore’s resulting holding stood at 263,073 shares. The same date also brought an award of 293,000 derivative securities, leaving Whittemore with 293,000 derivative …

Vinay Lochav | 14 September 2026

SpyGlass Pharma (NASDAQ:SGP) Edges Higher: Why Investors Are Reassessing the Stock

SpyGlass Pharma, Inc (NASDAQ:SGP) edged higher in a September 2026 session, drawing attention to one of the year's newer ophthalmology listings. Shares closed up 0.77% at $27.52 at last closing. The clinical-stage company is developing a novel drug-delivery approach for chronic eye disease, and …

Nitish Kishor | 14 September 2026

Fitzgerald Thomas A Receives 185,000 Derivative Securities Award

Fitzgerald Thomas A received 185,000 derivative securities in Transcode Therapeutics, Inc (NASDAQ: RNAZ). on 9 September 2026. The award left his resulting derivative securities position at 185,000, with the transaction representing about 100.0% of that holding.

Vinay Lochav | 14 September 2026
Support

Hi! How can we help you today?

Loading…